Skip to main content

Bexarotene Dosage

Medically reviewed by Last updated on Dec 7, 2023.

Applies to the following strengths: 75 mg

Usual Adult Dose for Cutaneous T-cell Lymphoma

300 mg/m2/day orally once a day with a meal

Duration of Therapy: This drug should be continued as long as the patient is deriving benefit. In clinical trials with CTCL patients, this drug was administered for up to 118 weeks.

Comments: If there is no tumor response after 8 weeks of treatment and the initial dose was well-tolerated, the dose may be escalated to 400 mg/m2/day with careful monitoring.

Use: Treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients refractory to at least one prior systemic therapy.

Renal Dose Adjustments

No adjustment recommended; however, caution is advised due to renal impairment potentially causing significant drug protein binding changes.

Liver Dose Adjustments

No adjustment recommended; however, caution is advised due to the potential of greatly decreased drug clearance.

Dose Adjustments

If Toxicity Occurs:

If Fasting Triglycerides are Elevated or Become Elevated During Treatment:


US BOXED WARNING: This drug should not be administered to pregnant women because it is a retinoid, a class of drugs associated with birth defects in humans. It has also caused birth defects in pregnant rats.

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available

Other Comments

Administration Advice:

Storage Requirements:



Patient Advice:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.